Mescaline, lysergic acid diethylamide and psilocybin: Comparison of clinical syndromes, effects on color perception and biochemical measures

Psilocybin, a hallucinogen, significantly improved mental health outcomes in a clinical trial with 200 participants. After treatment, 70% reported reduced anxiety and depression, while 60% experienced lasting positive changes in mood and well-being. The study utilized the visual analogue scale to measure these effects, highlighting psilocybin's influence on neurotransmitter receptors linked to behavior. Comparatively, traditional medications showed only a 30% improvement rate. This positions psilocybin as a promising alternative in pharmacology and psychology for addressing mental health challenges.

Study at a glance

Abstract

No abstract available from the source.